BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eurand Reports Recent Highlights and Financial Results for Third Quarter 2010


11/5/2010 9:10:49 AM

AMSTERDAM, THE NETHERLANDS--(Marketwire - November 05, 2010) - Eurand N.V. (NASDAQ: EURX)

Recent Highlights:

  • Record revenues of EUR 41.7 million ($56.7 million), up 36% from the third quarter of 2009

  • Net income of EUR 5.5 million ($7.5 million) versus a net loss of EUR 0.4 million ($0.5 million) in the third quarter of 2009

  • Revenues of EUR 21.8 million ($29.7 million) for the ZENPEP franchise, which includes ZENPEP® (pancrelipase) Delayed-Release Capsules and its 5,000-unit dose authorized generic, PANCRELIPASE™

  • For the week ended October 22, 2010, the ZENPEP franchise held 20% of the total market for all pancreatic enzyme products (PEPs), according to IMS Health Incorporated.

  • Increased total cash, cash equivalents and marketable securities to EUR 46.4 million ($63.1 million)

  • Phase III ZENPEP study recently initiated in Europe in exocrine pancreatic insufficiency (EPI) patients with cystic fibrosis

Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today reported record revenues of EUR 41.7 million ($56.7 million) for the third quarter of 2010, an increase of 36%, or 33% in constant currency, from the third quarter of 2009. Net income was EUR 5.5 million ($7.5 million), or EUR 0.11 ($0.16) per diluted share, compared with a net loss of EUR 0.4 million ($0.5 million), or a net loss of EUR 0.01 ($0.01) per diluted share, in the third quarter of 2009.

For the nine months ended September 30, 2010, revenues totaled EUR 105.7 million ($143.8 million), up 17%, or 13% in constant currency, from the same period of 2009. Net income for the first nine months of 2010 was EUR 2.5 million ($3.4 million), or EUR 0.05 ($0.07) per diluted share, compared with a net loss of EUR 2.0 million ($2.7 million), or a net loss of EUR 0.04 ($0.06) per diluted share, for the same period in 2009.

"The third quarter was very strong for Eurand, with revenues and profitability largely driven by the success of our ZENPEP franchise," said Gearóid Faherty, Chairman and Chief Executive Officer. "Less than a year after launch, ZENPEP is the second-most prescribed product in the U.S. pancreatic enzyme market, and the franchise currently holds a 20% share. We expect that the ZENPEP franchise will continue to grow for the rest of this year and into 2011 as physician and patient awareness increases."

ZENPEP Launch Update

Market share for the ZENPEP franchise grew substantially during the third quarter of 2010, with its share of total prescriptions in the pancreatic enzyme market expanding from 12% to 19%. Beginning with the week ended April 23, 2010 (prior to the FDA's enforcement of its April 28, 2010 Stop Distribution Date for certain unapproved PEPs) through the week ended October 22, 2010, ZENPEP's market share has more than tripled, from 6% to 20%.

"Even with the launch of a third FDA-approved PEP in mid-July, the ZENPEP franchise has continued to gain share at an impressive pace, and we are especially pleased by the positive feedback from physicians and patients regarding ZENPEP's ability to control the signs and symptoms of EPI, in particular for those patients who have switched from other PEPs," Faherty said. "We believe that ZENPEP's product characteristics and dosing options, coupled with broad access to the product through managed care and government reimbursement, have led to its significant market acceptance."

PRODUCT DEVELOPMENT PIPELINE UPDATE:

Eurand recently initiated a Phase III ZENPEP study in Europe in patients with EPI due to cystic fibrosis. The European Medicines Agency (EMA) has deemed a ZENPEP Marketing Authorization Application eligible for evaluation under the Centralized Procedure, which enables a single marketing authorization to be valid across the European Union and provides for 10 years of marketing exclusivity once the product is approved. Eurand plans to out-license the distribution rights for ZENPEP in Europe and other regions of the world, and discussions are ongoing with potential partners.

THIRD QUARTER 2010 FINANCIAL RESULTS

Total revenues were EUR 41.7 million ($56.7 million) in the third quarter of 2010, an increase of approximately 36%, or 33% at constant currency rates, compared with the third quarter of 2009. Product sales rose 51%, or 47% at constant currency rates, to EUR 37.9 million ($51.6 million) in the third quarter of 2010 compared with the same period of 2009. This increase is due to sales of ZENPEP and its authorized generic of EUR 21.8 million ($29.7 million), which more than offset the complete absence of sales of ULTRASE to Axcan and sales from Eurand's low-cost Pancrelipase. Both ULTRASE and Pancrelipase generated significant sales in 2009.

For the third quarter of 2010, product sales of ZENPEP and its authorized generic included revenues from shipments made in prior periods, which were deferred as of June 30, 2010 and amounted to EUR 4.9 million ($6.7 million). ZENPEP and its authorized generic revenues in excess of wholesalers' shipments to retail and non-retail channels were deferred in prior periods since wholesalers held inventories in excess of market needs due to the initial launch shipments. In the third quarter of 2010, wholesalers' inventories have been in line with market needs and therefore revenues were recognized on the basis of Eurand's shipments to wholesalers.

Royalties were EUR 2.2 million ($3.0 million), down 21% from the third quarter of 2009 due to negligible royalties (approximately EUR 0.1 million) from Axcan for ULTRASE. The currency exchange rate had no significant impact on the royalty income.

Development fees for the third quarter of 2010 were EUR 1.5 million ($2.1 million), down 43% from the same period in 2009. The currency exchange rate had no significant impact on the development fees. Revenue from development fees can fluctuate from quarter to quarter since a significant portion of fees is recognized upon achievement of development milestones.

Cost of goods sold was EUR 16.1 million ($21.9 million) for the three months ended September 30, 2010, up 4% from the same period in 2009. Excluding the impact of exchange rates, cost of goods sold would have been flat. The margin on product sales increased from 38.1% in the third quarter of 2009 to 57.4% in the third quarter of 2010, primarily as a result of higher-margin ZENPEP product sales. During the third quarter of 2010, Eurand sold some ZENPEP inventory that had been expensed in previous periods prior to receiving regulatory approval in the third quarter of 2009 for commercial launch in the U.S. If the related inventories were not expensed in previous periods, cost of goods sold in the three months ended September 30, 2010 would have been higher by approximately EUR 0.5 million ($0.7 million).

Research and development (R&D) expenses were EUR 5.7 million ($7.8 million) for the three months ended September 30, 2010, down approximately 11%, or 12% at constant currency rates, compared with the same period in 2009. Certain components of Eurand's R&D expenses, notably clinical studies, can vary significantly from quarter to quarter.

Selling, general and administrative (SG&A) expenses of EUR 13.6 million ($18.5 million) were up 73%, or 71% at constant currency rates, compared with the third quarter of 2009. The increase in SG&A expenses is primarily attributable to an increase in direct sales and marketing expenses associated with the November 2009 launch of ZENPEP, the expansion of the sales force, and related marketing, patient support and managed-care programs.

Net income was EUR 5.5 million ($7.5 million) for the third quarter of 2010 compared with a net loss of EUR 0.4 million ($0.5 million) in the same period of 2009. Net income per diluted share was EUR 0.11 ($0.16) versus a net loss of EUR 0.01 ($0.01) per diluted share in the comparable period of 2009.

At September 30, 2010, cash, cash equivalents and marketable securities were EUR 46.4 million ($63.1 million), and debt was EUR 2.8 million ($3.7 million).

YEAR-TO-DATE 2010 FINANCIAL RESULTS

Total revenues were EUR 105.7 million ($143.8 million) for the nine months ended September 30, 2010, an increase of 17%, or 13% at constant currency rates, compared with the same period in 2009. The growth in revenues can be primarily attributed to sales of ZENPEP and its authorized generic.

Product sales grew 29%, or 24% at constant currency rates, to EUR 94.2 million ($128.1 million) year to date in 2010 compared with the same period of 2009. Product sales of ZENPEP and its authorized generic included revenues from sales made in 2009, which were deferred as of December 31, 2009 and amounted to EUR 3.7 million ($5.0 million).

Royalties of EUR 6.9 million ($9.4 million) were down 15%, or 16% at constant currency rates, compared with the first nine months of 2009 due to lower royalties from Axcan for ULTRASE. Development fees were EUR 4.6 million ($6.3 million), down 49% from the prior year period, which included a milestone payment from GlaxoSmithKline related to the launch of LAMICTAL® ODT™.

Cost of goods sold was EUR 44.5 million ($60.5 million) for the nine months ended September 30, 2010, down 2% from the prior year period, or 5% at constant currency rates. During the nine months ended September 30, 2010, Eurand sold some inventories of ZENPEP that were expensed in previous periods prior to receiving regulatory approval in the third quarter of 2009 for commercial launch in the U.S. If the related inventories were not expensed in previous periods, cost of goods sold in the nine months ended September 30, 2010 would have been higher by approximately EUR 1.0 million ($1.4 million).

The margin on product sales was 52.7% year to date in 2010 versus 38.0% in the first nine months of 2009 as a result of higher-margin ZENPEP sales in 2010.

R&D expenses were EUR 16.7 million ($22.7 million) for the nine months ended September 30, 2010, down 8%, or 10% in constant currency rates, compared with the same period in 2009. SG&A expenses of EUR 38.7 million ($52.6 million) were up 58%, or 53% at constant currency, compared with the year to date in 2009 due primarily to the increased direct sales and marketing costs associated with the launch of ZENPEP and expansion of the sales force.

Net income was EUR 2.5 million ($3.4 million) for the first nine months of 2010 compared with a net loss of EUR 2.0 million ($2.7 million) in the same period of 2009. Net income per diluted share was EUR 0.05 ($0.07) versus a net loss of EUR 0.04 ($0.06) per diluted share in the comparable period of 2009.

Attached to this earnings release are the following items:

1. Selected unaudited consolidated statements of operations for the three months ended September 30, 2010 compared with the same period in 2009

2. Selected unaudited consolidated statements of operations for the nine months ended September 30, 2010 compared with the same period in 2009

3. Selected unaudited balance sheet data as of September 30, 2010 and December 31, 2009

Note on Currency Presentation

This press release contains translations of euros into U.S. dollars at a convenience rate of EUR 1=$1.360, the noon buying rate at the Federal Reserve Bank of New York on September 30, 2010.

Percentage variances quoted in "Constant Currency" represent the increase or decrease recomputed as if euro/dollar exchange rates had been the same in the three and nine months ended September 30, 2010 as they were in the same period in 2009. As a guide, average exchange rates were EUR 1=$1.291 in the three months to September 30, 2010, EUR1=$1.316 in the nine months to September 30, 2010, EUR 1=$1.431 in the three months to September 30, 2009, and EUR1=$1.365 in the nine months to September 30, 2009.

Conference Call Information

Eurand will host a conference call today, Friday, November 5, 2010, at 8:30 a.m. Eastern Time, 1:30 p.m. Central Europe Time, covering the third quarter and nine-months 2010 financial results.

To participate in the conference call, U.S. participants dial 1-877-407-9039, international participants dial +1-201-689-8470. A replay of the call will be available until December 5, 2010. For a replay of the call, U.S. participants dial 1-877-870-5176, international participants dial +1-858-384-5517. The conference ID number is 358370.

A live webcast of the call also will be available from the investor relations section of the company website at www.eurand.com. Following the live webcast, the archived version of the call will be available at the same URL until December 5, 2010.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.

Forward-Looking Statements

This release and oral statements made with respect to information contained in this release, including statements about the market potential of ZENPEP, constitute forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. The words "expects," "potentially," "anticipates," "could," "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include, risks associated with our ability to market, commercialize and achieve market acceptance for ZENPEP, or for any of the products that we are developing or commercializing or may develop or commercialize in the future. A non-exclusive list of important factors that may affect future results may be found in Eurand's filings with the Securities and Exchange Commission, including its annual report on Form 20-F and periodic reports on Form 6-K. Investors should evaluate any statement in light of these important factors. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.

Item 1. Selected unaudited consolidated statements of operations for the three months ended September 30, 2010 compared with same period in 2009

                      Three months ended September 30,                      
                            2010       2010       2009       % Change       
                                                              At         At 
                                                         current   constant 
                        $'000(a)   euro'000   euro'000  currency   currency 
                                                                            
Product sales             51,576     37,921     25,053        51%        47%
Royalty income             3,043      2,237      2,815       -21%       -22%
Development fees           2,099      1,543      2,723       -43%       -44%
                                                                            
                      ---------- ---------- ---------- --------- ---------- 
Total revenues            56,718     41,701     30,591        36%        33%
Cost of goods sold       (21,945)   (16,135)   (15,517)        4%         0%
R & D expenses            (7,796)    (5,732)    (6,473)      -11%       -12%
S,G & A expenses         (18,479)   (13,586)    (7,855)       73%        71%
Amortization of                                                             
 intangibles                (422)      (310)      (336)       -8%        -9%
Other expenses               (49)       (36)         -      N.M.       N.M. 
                                                                            
                      ---------- ---------- ---------- --------- ---------- 
Operating income           8,027      5,902        410      N.M.       N.M. 
                                                                            
Financial income              57         42        117      N.M.       N.M. 
                                                                            
                      ---------- ---------- ---------- --------- ---------- 
Income before taxes        8,084      5,944        527      N.M.       N.M. 
                                                                            
Income taxes                (593)      (436)      (921)     N.M.       N.M. 
                                                                            
                      ---------- ---------- ---------- --------- ---------- 
Net income (loss)          7,491      5,508       (394)     N.M.       N.M. 
                                                                            
                      ========== ========== ========== ========= ========== 
Basic net income                                                            
 (loss) per share          $0.16   EUR 0.11  EUR (0.01)                     
Diluted net income                                                          
 (loss) per share          $0.16   EUR 0.11  EUR (0.01)                     
Weighted average                                                            
 number of shares used                                                      
 to compute basic                                                           
 income (loss) per                                                          
 share                47,949,373 47,949,373 45,775,720                      
Weighted average                                                            
 number of shares used                                                      
 to compute diluted                                                         
 income (loss) per                                                          
 share                48,233,508 48,233,508 45,775,720                      
                                                                            
                                                                            
(a) Figures in U.S. dollars are translated from the euro for convenience, at
    a rate of 1Euro=$1.360, the noon buying rate at the Federal Reserve Bank
    of New York on September 30, 2010.                                      

Item 2. Selected unaudited consolidated statements of operations for the nine months ended September 30, 2010 compared with the same period in 2009

                       Nine months ended September 30,                      
                            2010       2010       2009       % Change       
                                                              At         At 
                                                         current   constant 
                        $'000(a)   euro'000   euro'000  currency   currency 
                                                                            
Product sales            128,132     94,208     73,151        29%        24%
Royalty income             9,363      6,884      8,113       -15%       -16%
Development fees           6,263      4,605      9,035       -49%       -51%
                                                                            
                      ---------- ---------- ---------- --------- ---------- 
Total revenues           143,758    105,697     90,299        17%        13%
Cost of goods sold       (60,543)   (44,514)   (45,327)       -2%        -5%
R & D expenses           (22,677)   (16,673)   (18,196)       -8%       -10%
S,G & A expenses         (52,611)   (38,682)   (24,505)       58%        53%
Amortization of                                                             
 intangibles              (1,262)      (928)    (1,038)      -11%       -13%
Other expenses              (690)      (507)         -      N.M.       N.M. 
                                                                            
                      ---------- ---------- ---------- --------- ---------- 
Operating income           5,975      4,393      1,233      N.M.       N.M. 
                                                                            
Financial income                                                            
 (loss)                      760        559        (52)     N.M.       N.M. 
                                                                            
                      ---------- ---------- ---------- --------- ---------- 
Income before taxes        6,735      4,952      1,181      N.M.       N.M. 
                                                                            
Income taxes              (3,342)    (2,457)    (3,151)     N.M.       N.M. 
                                                                            
                      ---------- ---------- ---------- --------- ---------- 
Net income (loss)          3,393      2,495     (1,970)     N.M.       N.M. 
                                                                            
                      ========== ========== ========== ========= ========== 
Basic net income                                                            
 (loss) per share          $0.07   EUR 0.05  EUR (0.04)                     
Diluted net income                                                          
 (loss) per share          $0.07   EUR 0.05  EUR (0.04)                     
Weighted average                                                            
 number of shares used                                                      
 to compute basic                                                           
 income (loss) per                                                          
 share                47,907,096 47,907,096 45,761,056                      
Weighted average                                                            
 number of shares used                                                      
 to compute diluted                                                         
 income (loss) per                                                          
 share                48,381,986 48,381,986 45,761,056                      
                                                                            
                                                                            
(a) Figures in U.S. dollars are translated from the euro for convenience, at
    a rate of 1Euro=$1.360, the noon buying rate at the Federal Reserve Bank
    of New York on September 30, 2010.                                      

Item 3. Selected unaudited balance sheet data as of September 30, 2010 and December 31, 2009

                                            September 30,       December 31,
                                              2010         2010         2009
                                         $'000 (1)     euro'000     euro'000
                                                                            
Cash and cash equivalents                   37,883       27,853       16,893
Marketable securities                       25,216       18,540       23,049
Total debt                                   3,740        2,750          207
Total shareholders' equity                 157,644      115,906      111,574
                                                                                
(1) Figures in U.S. dollars are translated from the euro for convenience, at a  
    rate of 1Euro=$1.360, the noon buying rate at the Federal Reserve Bank of   
    New York on September 30, 2010.                                             

Contacts:

Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1 267-759-9335
Email Contact

Nick Laudico/Sara Pellegrino
The Ruth Group
+1 646-536-7030/7002
Email Contact
Email Contact



Read at BioSpace.com

Eurand
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES